Doctor Susana Del Prado Diaz
Ramon and Cajal University Hospital, Madrid (Spain)
Empagliflozin in heart failure: beyond clinical endpoints
Event: Heart Failure 2019
Topic: Pharmacotherapy
Session: Chronic Heart Failure – Treatment
Prognostic significance of biomarkers in infective endocarditis
Event: Heart Failure 2019
Topic: Epidemiology, Prognosis, Outcome
Session: Valvular Heart Disease
Sacubitril-valsartan and its effect on ventricular remodeling
Event: Heart Failure 2019
Topic: Pharmacotherapy
Session: Chronic Heart Failure – Treatment
Effect of empagliflozin on hydroelectrolytic balance in patients with heart failure with reduced ejection fraction
Event: Heart Failure 2019
Topic: Cardiovascular Pharmacotherapy, Other
Session: Pharmacology and Pharmacotherapy
Sacubitril-valsartan and BNP: Will they live happily ever after?
Event: Heart Failure 2018
Topic: Biomarkers
Session: Chronic Heart Failure – Diagnostic Methods
Defining heart failure with mid-range ejection fraction
Event: Heart Failure 2018
Topic: Clinical, Other
Session: Chronic Heart Failure - Clinical
Role of right ventricle in heart failure
Event: Heart Failure 2018
Topic: Clinical, Other
Session: Chronic Heart Failure - Clinical
What is the significance of right ventricular dysfunction in patients with preserve, mid-range and depressed LVEF?
Event: Heart Failure 2018
Topic: Systolic Ventricular Dysfunction
Session: Chronic Heart Failure – Pathophysiology and Mechanisms
Differences in biomarkers and biochemical parameters between heart failure with severely depressed and mid range ejection fraction
Event: Heart Failure 2018
Topic: Heart Failure with Mid-Range Ejection Fraction (HFmrEF)
Session: Chronic Heart Failure – Pathophysiology and Mechanisms
ECMO as bridge to surgery in post-infart ventricular septal defect
Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure
Topic: Devices / Artificial heart / CRT / ICD
Session: Clinical Case Corner 4 - CAD and heart failure: a liaison dangereuse
ESC 365 is supported by
